Study details
Enrolling now
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD
Massachusetts General Hospital
NCT IDNCT07079761ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
96
Study length
about 1.7 years
Ages
18–55
Locations
1 site in MA
What this study is about
Researchers are testing whether a single intravenous dose of allopregnanolone (Allo) compared to placebo promotes consolidation of extinction learning or blocks reconsolidation of physiological responses triggered by aversive memories. The trial also tests if Allo affects retention of non-aversive memories.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Participate in Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm
- 2.Participate in Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm
- 3.Participate in Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
- +2 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
infusion
Body systems
Psychiatry / Mental Health